The 28 references in paper O. Beresneva N., M. Parastaeva M., G. Ivanova T., A. Kucher G., I. Kayukov G., О. Береснева Н., М. Парастаева М., Г. Иванова Т., А. Кучер Г., И. Каюков Г. (2006) “РОЛЬ КЕТОСТЕРИЛА В НЕФРОПРОТЕКЦИИ И КАРДИОПРОТЕКЦИИ ПРИ ЭКСПЕРИМЕНТАЛЬНОЙ УРЕМИИ // THE ROLE OF KETOSTERIL IN NEPHROPROTECTION AND CARDIOPROTECION IN EXPERIMENTAL UREMIA” / spz:neicon:nefr:y:2006:i:1:p:56-61

1
Волгина ГВ. Клиническая эпидемиология кардиовас­ кулярных нарушений при ХПН (обзор литературы). Нефро­ логия и диализ 2000; 2(1-2): 25-32
(check this in PDF content)
2
Шишкин АН. Современные проблемы уремической кардиопатии. Нефрология 2003; 7(1): 14-20.
(check this in PDF content)
3
Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41 [Suppl 5]: 11-17
(check this in PDF content)
4
Смирнов АВ, Добронравов ВА, Румянцев АШ и др. Факторы риска ИБС у больных, получающих лечение ге­ модиализом. Нефрология 2003; 7[Приложение 1]: 7-13
(check this in PDF content)
5
Шутов АМ, Куликова ЕС, Кондратьева НИ. Гипертро­ фия левого желудочка у больных в додиализном периоде хронической почечной недостаточности, не связанной с сахарным диабетом. Нефрология 2001; 5( 5): 49-53
(check this in PDF content)
6
London GM. Pathophysiology of cardiovascular damage in the early renal population. Nephrol Dial Transpl 2001; 16[2 Suppl ]: 3-6
(check this in PDF content)
7
McCullough PA, Sandberg KR, Dumler F, Yanez JE. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 2004; 17(2): 205- 215
(check this in PDF content)
8
Varizi ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Diseas 2001; 38(4): S74-79
(check this in PDF content)
9
Бреннер БМ. Механизмы прогрессирования болез­ ней почек. Нефрология 1999; 3(4): 23-27
(check this in PDF content)
10
Pozoni P, Del Vecchio L, Locatelli F. Pharmacological prevention of kidney diseases. G Ital Nefrol 2003; 20(Suppl 22): 3-11
(check this in PDF content)
11
Schaefer L, Meier K, Hafner C et al. Protein restriction influences glomerular matrix turnover and tubular hypertrophy by modulation on renal proteinase activities. Mineral Electrol Metab 1996; 22(1-3): 162-167
(check this in PDF content)
12
Kopple JD, Levey AS, Greene T et al. Effect of dietary protein restriction on nutritional status in the modification of diet in renal disease study. Kidney Int 1997; 52(3): 778-791
(check this in PDF content)
13
Polzin D J, Osborne CA, Ross S, Jacob F. Dietary management of feline: where are we now? In what direction are we headed? J Feline Med Surg 2000; 2: 75-82
(check this in PDF content)
14
Doi SQ, Rasaiah S, Tack J et al. Low-protein diet suppresses serum insulin-like growth factor-1 and decelerates the progression of growth hormone-induced glomerulosclerosis. Am J Nephrol 2001; 21(4): 331-339
(check this in PDF content)
15
Лифшиц НИ, Николаев АЮ. Применение диеты различным содержанием белка в сочетании с кетоанало- гами незаменимых аминокислот при лечении хроничес­ кой почечной недостаточности. Современное состояние проблемы. Тер архив 1999; 71(1): 74-77
(check this in PDF content)
16
Ayli M, Ensari C, Mandiroglu F, Allioglu M. Effect of low-ptotein diet supplemented with keto acids on progression of disease in patients with chronic renal failure. Nephron 2000; 84(3): 288-289
(check this in PDF content)
17
Druml W. Supplemets of keto acids in patients with chronic renal failure - more than modulators of nitrogen economy. Wien Klin Wochenscher 2001; 113(17-18): 638­ 640
(check this in PDF content)
18
Passey C, Bunker V, Jackson A, Lee H. Energy balance in predialysis patients on a low-protein diet. J Ren Nutr 2003; 13(2): 120-125
(check this in PDF content)
19
Prakash S, Pande DP, Sharma S et al. Randomized, double-blind, placebo-controlled trial to evaluate efficacy of ketodiet in predialytic chronic renal failure. National Kidney Foundation 2004; 14(2): 89-96
(check this in PDF content)
20
Foley RN, Parfrey PS. Cardiac disease in chronic uremia: clinical outcome and risk factors. Adv Renal Replace Ther 1997; l4: 234-248
(check this in PDF content)
21
Lim U, Cassano PA. Homocystein and blood pressure in the Third National Health Nutrition Examination Survey, 1988­ 1994. Am J Epidemiol 2002; 156(12): 105-113
(check this in PDF content)
22
Amann K, Tornig J, Kugel B et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003; 63(4): 1296-1301
(check this in PDF content)
23
Smogorzewski M. PTG, chronic renal failure and myocardium. Miner Electrol Metab 1995; 21(1-3): 55-62
(check this in PDF content)
24
Барабанова ВВ, Береснева ОН. Является ли парати­ реоидный гормон основным повреждающим фактором со­ судов печени при экспериментальной почечной недостаточности. Нефрология 1998; 2(1): 99-104
(check this in PDF content)
25
Qing DP, Ding H, Vadgama J et al. Elevated myocardial cytosolic calcium impairs insulin-like growth factor-1 - stimulated protein synthesis in chronic renal failure. J Am Soc Nephrol 1999;10(1):84-92
(check this in PDF content)
26
Combe C, Aparicio M. Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 1994; 46: 1381-1386
(check this in PDF content)
27
Lafage-Proust MH, Combe C, Barthe N, Aparicio M. Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction. J Clin Endocrin Metab 1999; 84(2): 512-519
(check this in PDF content)
28
Martinez I, Saracho R, Ocharan J et al. Role of diet in the management of osteodystrophy during progressive renal insufficiency. Nefrologia 2003; 23 [Suppl 2]: 57-63 Поступила в редакцию 09.11.2005 г.
(check this in PDF content)